The dynamic field of translational medicine, particularly in the context of cutting-edge cell and gene therapies, is reshaping the role of academic research centers. This session will discuss optimizing the academic research framework for clinical relevance, focusing on regulatory science, accessibility, stakeholder engagement, and organizational optimization.

Academic institutions are increasingly pressurized to drive the progression from pre-clinical stages to clinical trials, with the potential to achieve market authorization. With the rising interest in academic drug development and the backdrop of healthcare sustainability challenges, there's a growing shift of public funding towards research collaborations focused on clinical applications. However, institutions often lack the specific capacity, knowledge and focus, which are essential for successfully navigating the entire development pathway to market authorization.

The session will explore pivotal areas for researchers in translational medicine, stressing the importance of translatable approaches for research impact. Accessibility, including regulatory navigation and Health Technology Assessment, is vital for successful translation and influences funding and EU legislation debates. Engaging stakeholders strategically is crucial for aligning therapies with clinical goals and patient expectations. Finally, the need for organizational innovation is discussed, highlighting strategies for cross-disciplinary collaboration and rethinking structures to support research's transformation into clinically impactful therapies.